KR960010006A - Way - Google Patents

Abstract

1. The technical field to which the invention described in the claims belongs.

Pharmaceutical Uses of Azaspiran Derivatives

2. The technical problem to be solved by the invention

Treatment method of hyperlipidemia in mammal using azaspiran derivative

3. Summary of how to solve the technical problem

Pharmaceutical composition containing a carrier of azaspiran derivative

4. Important uses of the invention

Hyperlipidemia Drug

Description

Hyperlipidemia Treatment

Since this is an open matter, no full text was included.

Claims (43)

A method of treating hyperlipidemia by administering to a mammal, including humans, an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof; (Ⅰ) Wherein n is 1 or 2, and R ¹ and R ² are the same or different and are selected from hydrogen or straight chain, branched or cyclic alkyl, provided that the sum of the carbon numbers of R ¹ and R ² is 0 to 10; Or R ¹ and R ² join together to form a cyclic alkyl group having 3 to 7 carbon atoms; R ³ and R ⁴ are the same or different and are selected from hydrogen or methyl. The process of claim 1 wherein the compound is 2- [2- (dimethylamino) ethyl] -8,8-dipropyl-2-azaspiro [4,5] decane. The method of claim 1 wherein the mammal is a human. The method of claim 1, wherein the mammal suffers from hyperlipidemia The method of claim 1, wherein the mammal suffers from atherosclerosis. The method of claim 1, wherein the mammal suffers from transplanted atherosclerosis. The method of claim 1, wherein the mammal requires lower cholesterol and triglyceride levels The method of claim 1, wherein the mammal needs lower cholesterol levels. The method of claim 1, wherein the mammal requires lower triglyceride levels. The method of claim 1, wherein the mammal requires lower low-density lipoprotein levels The method of claim 1, wherein the compound is orally administered The method of claim 11, wherein the compound is administered from about 0.01 mg / kg to about 30 mg / kg per day. The method of claim 1, wherein the compound is parenterally administered. The method of claim 13, wherein the compound is administered from about 0.01 mg / kg to about 30 mg / kg per day. Use of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof for the manufacture of a medicament for the treatment of hyperlipidemia in a mammal, including humans: (Ⅰ) Wherein n is 1 or 2, and R ¹ and R ² are the same or different and are selected from hydrogen or straight chain, branched or cyclic alkyl, provided that the sum of the carbon numbers of R ¹ and R ² is 0 to 10; Or R ¹ and R ² join together to form a cyclic alkyl group having 3 to 7 carbon atoms; R ³ and R ⁴ are the same or different and are selected from hydrogen or methyl. Use according to claim 15, wherein the compound is 2- [2- (dimethylamino) ethyl] -8,8-dipropyl-2-azaspiro [4,5] decane. Use according to claim 15, wherein the mammal is a human. Use according to claim 15, wherein the mammal suffers from hyperlipidemia. Use according to claim 15, wherein the mammal suffers from atherosclerosis. Use according to claim 15, wherein the mammal suffers from transplanted atherosclerosis. Use according to claim 15, wherein the mammal requires lower cholesterol and triglyceride levels. Use according to claim 15, wherein the mammal needs lower cholesterol levels. Use according to claim 15, wherein the mammal needs lower triglyceride levels. The use of claim 1, wherein the mammal requires lower low-density lipoprotein levels. Use according to claim 15 for oral administration of a compound. The use of claim 25 for administering from about 0.01 mg / kg to about 30 mg / kg of compound per day. Use according to claim 15 for parenteral administration of the compound. The use of claim 27, wherein the compound is administered from about 0.01 mg / kg to about 30 mg / kg per day. A pharmaceutical composition for treating hyperlipidemia in a mammal, including a human, comprising a compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable carrier: (Ⅰ) Wherein n is 1 or 2, and R ¹ and R ² are the same or different and are selected from hydrogen or straight chain, branched or cyclic alkyl, provided that the sum of the carbon numbers of R ¹ and R ² is 0 to 10; Or R ¹ and R ² join together to form a cyclic alkyl group having 3 to 7 carbon atoms; R ³ and R ⁴ are the same or different and are selected from hydrogen or methyl. The composition of claim 29 wherein the compound is 2- [2- (dimethylamino) ethyl] -8,8-dipropyl-2-azaspiro [4,5] decane The composition of claim 29 wherein the mammal is a human 30. The composition of claim 29, wherein the mammal has hyperlipidemia The composition of claim 29, wherein the mammal suffers from atherosclerosis. 30. The composition of claim 29, wherein the mammal is suffering from transplanted atherosclerosis. The composition of claim 29, wherein the mammal requires lower cholesterol and triglyceride levels. The composition of claim 29, wherein the mammal requires lower cholesterol levels. The composition of claim 29, wherein the mammal requires lower triglyceride levels. The composition of claim 29, wherein the mammal requires lower low-density lipoprotein levels. The composition of claim 29 wherein the compound is orally administered The composition of claim 39, wherein the compound is administered from about 0.01 mg / kg to about 30 mg / kg per day. The composition of claim 29, wherein the compound is parenterally administered. The composition of claim 41 wherein the compound is administered from about 0.01 mg / kg to about 30 mg / kg per day. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula (Ⅰ) ※ Note: The disclosure is based on the initial application.